Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | CXCR4 in Waldenström’s macroglobulinemia

Zachary Hunter • 14 Sep 2019
IMW 2019
Rare Diseases Waldenström’s Macroglobulinemia

Zachary Hunter, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the genomic basis of Waldenström’s Macroglobulinemia at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Zachary Hunter

Using genomics to understand ibrutinib resistance in Waldenström's macroglobulinemia
0:57
Using genomics to understand ibrutinib resistance in Waldenström's macroglobulinemia
Zachary Hunter • 19 Oct 2024
Multi-omic analysis in WM: progress being made and challenges that remain
1:11
Multi-omic analysis in WM: progress being made and challenges that remain
Zachary Hunter • 19 Oct 2024
Flow cytometry can detect changes in protein expression throughout the evolution of WM
1:12
Flow cytometry can detect changes in protein expression throughout the evolution of WM
Zachary Hunter • 10 Dec 2023
Quantifying mutant MYD88 expression to track disease burden in WM
1:33
Quantifying mutant MYD88 expression to track disease burden in WM
Zachary Hunter • 10 Dec 2023

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals